Delphine Lebon

2 days ago | nature.com | Delphine Lebon |Nicolas Duployez |Christophe Willekens |Thomas Cluzeau |Christian Récher |Mathilde Hunault-Berger | +1 more

AbstractFront-line treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in patients with low-/intermediate-risk acute promyelocytic leukemia (APL). However, for high-risk (HR) patients (defined as those with a white blood cell count ≥ 10×10⁹/L), the role of ATRA-ATO is subject to debate, and study data are scarce.

Feb 9, 2024 | onlinelibrary.wiley.com | Delphine Lebon |Stefan Djordjevic |Louison Collet |Cathy Gomila

1 INTRODUCTION Leukemogenesis in acute myeloid leukemia (AML) is a complex but poorly understood process, triggered by uncontrolled proliferation of immature cells.